Update on androgenicity

American Journal of Obstetrics and Gynecology

Volumn 180, Issue 2 II, 1999, Pages

  Thorneycroft, I H ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Acne; Androgenicity; Atherosclerosis; Progestogens; Third generation oral contraceptives; Venous thromboembolism

Indexed keywords

CYPROTERONE ACETATE; DESOGESTREL; GESTODENE; LEVONORGESTREL; NORETHISTERONE;

ACNE; ATHEROSCLEROSIS; CONFERENCE PAPER; DOSE RESPONSE; DRUG FORMULATION; DRUG MIXTURE; DRUG SAFETY; HEART INFARCTION; HIRSUTISM; HUMAN; LIPID SOLUBILITY; ORAL CONTRACEPTION; PRIORITY JOURNAL;

EID: 0033026414     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9378(99)70720-9     Document Type: Conference Paper

References (27)

1. GV Upton A. Corbin The relevance of the pharmacologic properties of a progestational agent to its clinical effects as a combination oral contraceptive Yale J Biol Med 62 1989 445 457
2. N Van der Vange MA Blankenstein HJ Kloosterboer AA Haspels JH Thijssen Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroids binding globulin, total and free testosterone Contraception 41 1990 345 352
3. DL Cassidenti RJ Paulson P Serafini FZ Stanczyk RA Lobo Effects of sex steroids on skin 5 alpha-reductase activity in vitro Obstet Gynecol 78 1991 103 107
4. MR Adams TB Clarkson DR Koritnik HA Nash Contraceptive steroids and coronary artery atherosclerosis in cynomolgus macaques Fertil Steril 47 1987 1010 1017
5. TB Clarkson MR Adams JR Kaplan CA Shively DR Koritnik From menarche to menopause: coronary artery atherosclerosis and protection in cynomolgus monkeys Am J Obstet Gynecol 160 1989 1280 1285
6. HJ Engel E Engel PR Lichtlen Coronary atherosclerosis and myocardial infarction in young women: role of oral contraceptives Eur Heart J 4 1983 1 6
7. M Notelovitz EB Feldman M Gillespy J. Gudat Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative 12-month clinical trial Am J Obstet Gynecol 160 1989 1269 1280
8. W Patsch SA Brown AM Gotto RL Young The effect of triphasic oral contraceptives on plasma lipids and lipoproteins Am J Obstet Gynecol 161 1989 1396 1401
9. MA Lewis WO Spitzer LA Heinemann KD MacRae R Bruppacher M. Thorogood Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women BMJ 312 1996 88 90
10. S Suissa L Blais WO Spitzer J Cusson M Lewis L. Heinemann First-time use of newer oral contraceptives and the risk of venous thromboembolism Contraception 56 1997 141 146
11. RJ Pye G Meyrick MJ Pye JL Burton Effect of oral contraceptives on sebum excretion rate BMJ 2 1977 1581 1582
12. R Palatsi E Hirvensalo P Liukko T Malmiharju L Mattila P Riihiluoma Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives Acta Derm Venereol 64 1984 517 523
13. A Lemay SD Dewailly R Grenier J. Huard Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethinyl estradiol and D,L -norgestrel J Clin Endocrinol Metab 71 1990 8 14
14. JM Wishart An open study of Triphasil and Diane 50 in the Treatment of acne Australas J Dermatol 32 1991 51 54
15. GP Redmond WH Olson JS Lippman ME Kafrissen TM Jones JL Jorizzo Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial Obstet Gynecol 89 1997 615 622
16. RK Percival-Smith AA Yuzpe JA Desrosiers JE Rioux E. Guilbert Cycle control on low-dose oral contraceptives: a comparative trial Contraception 42 1990 253 262
17. E Hirvonen M Malkonen V. Manninen Effects of different progestogens on lipoproteins during postmenopausal replacement therapy N Engl J Med 304 1981 560 563
18. P Croft PC Hannaford Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners’ oral contraception study BMJ 298 1989 165 168
19. World Health Organization Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 1995 1582 1588
20. World Health Organization Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 1995 1575 1582
21. G. Weiss Gyn Committee assesses VTE and oral contraceptive link ACOG Newslett Dec 1996 3 4
22. H Jick SS Jick V Gurewich M Wald Meyers C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
23. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen Lancet 346 1995 1593 1596
24. WO Spitzer MA Lewis LA Heinemann M Thorogood KD MacRae Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women BMJ 312 1996 88 90
25. J Rosing G Tans GA Nicolaes MC Thomassen R Van Oerie PM van der Ploeg Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives Br J Haematol 97 1997 233 238
26. W Schramm LA Heinemann Oral contraceptives and venous thromboembolism: acquired APC resistance [letter] Br J Haematol 98 1997 491
27. J Rosing HC Hemker G. Tans Oral contraceptives and venous thromboembolism: acquired APC resistance [letter] Br J Haematol 98 1997 491 492